Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANOPY-N neoadjuvant canakinumab and/or pembrolizumab in resectable NSCLC
NL-OMON55116Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Canakinumab monotherapy, Pembrolizumab monotherapy and Canakinumab + pembrolizumab (3 arms). Primary endpoint: Major pathological response rate by central assessment. Started May 2020; status: active, not recruiting.
02
Drugs
canakinumabpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON55116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55116.